FDA announced a Public Advisory Committee Meeting

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -

Save the Date

ISSWSH Sexual Pain Course 2020
April 17-18, 2020
CANCELLED DUE TO COVID-19
Read more...

ISSWSH Fall Course 2020
November 19-21, 2020   235 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2021
March 4-7, 2021   340 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

“No research can be truly meaningful if there is not a regulatory agency that will allow developers to put forward… https://t.co/lGlT88qH4U ISSWSH
Time to Orgasm in Women in a Monogamous Stable Heterosexual Relationship was 13 minutes in this study. https://t.co/3ovAvTUcRa ISSWSH
Endometriosis apps include symptom trackers, education, & support for women w/this condition. Do apps have a role i… https://t.co/4T9KMOVJm3 ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!